A 26-Week Randomized Controlled Trial of Semaglutide Once Daily Versus Liraglutide and Placebo in Patients With Type 2 Diabetes Suboptimally Controlled on Diet and Exercise With or Without Metformin

Once-daily semaglutide at doses up to 0.3 mg/day resulted in greater reductions in HbA_1c compared with liraglutide or placebo but with a higher frequency of GI AEs.